地赐康对高脂血症患者sICAM-1及sVCAM-1的影响

目的:观察地赐康对高脂血症患者可溶性黏附分子的影响。方法:治疗组90例原发性高脂血症患者给地赐康冲剂1袋,tid,疗程8周,于治疗前、后测可溶性细胞间黏附分子—1(sICAM-1)和可溶性血管内皮细胞黏附分子—1(sVCAM—1)含量。对照组30例正常者,于试验前测sICAM-1及sVCAM—1含量。结果:治疗组sICAM—1及sVCAM—1均增高,与对照组比较差异有显著性。治疗8周后,治疗组可使sICAM—1和sVCAM—1明显下降(分别为27.4％及18％)P均<0.01,且治疗组用药期间未出现明显不良反应。结论:地赐康可有效降低高脂血症患者sICAM-1及sVCAM—1的含量,且依从性好,服用安全。

The influence of Dicikang on sICAM-1 and sVCAM-1 in hyperlipoproteinemia patients

Objective:To observe the influence of Dicikang on sICAM-1 and sVCAM-1 in hy-perlipoproteinemia(HLP) patients. Methods:90 patients with primary HLP in the active group were given Dicikang preparations 1 bag for 8 weeks;the 30 normal persons in the control group were measured the level of sICAM-1 and sVCAM-1 before test. Results:The level of sICAM-1 and sVCAM-1 in the HLP patients were all increased and there was significant difference between the two groups. After treatment for 8 weeks, sICAM-1 and sVCAM-1 in the active group were obviously decreased by 27.4% and 18% (P<0.01). The active group had no obvious side-effects during the treatment. Conclusion: Dicikang can reduce the content of sICAM-1 and sVCAM-1 in HLP patients and has good compliance.